Hikma appoints Julie Hill as Senior Vice President

Press Release Leadership 1 February 2024

Hikma appoints Julie Hill, as Senior Vice President, Corporate Quality Compliance/Health and Safety

London 1 February 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that Julie Hill has been appointed Senior Vice President, Corporate Quality Compliance/Health and Safety, effective immediately.

Julie will report to Hikma’s CEO, Riad Mishlawi, and she will also join the company’s senior management as a member of Hikma’s Executive Committee.

“Julie’s appointment to this role is a great recognition of her outstanding leadership qualities, valuable insights, and her ability to contribute significantly to Hikma’s continued growth and success,” said Riad Mishlawi, Hikma’s CEO.

Julie joined Hikma through the 2016 acquisition of Roxane Laboratories and most recently served as Vice President, Quality, for Hikma’s Generics business. Under Julie’s leadership, Hikma’s Generics team and Columbus facility have had the distinction of achieving many successful quality inspections from the US Food and Drug Administration and the regulatory bodies of multiple other nations.

Download press release

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes.